Yarosh DB, Cruz PD, Dougherty I, Bizios N, Kibitel J, Goodtzova K, Both D, Goldfarb S, Green B, Brown D. FRAP DNA-dependent protein kinase mediates a late signal transduced from ultraviolet-induced DNA damage. J Invest Dermatol. 2000 May; 114(5):1005-10.
Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs M, Witmer M, Van Gorp WG, Fornier M, D’Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie V, Theodoulou M, Norton L, and Hudis C. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient’s perspective. Breast Cancer ResTreat. 2006 Aug; 98:343-348.
Horwitz S, Foss F, Goldfarb S, Molina A, Hamlin P, O’Connor O, Cammarata M, Moskowitz C and Zelenetz A. FDG-PET scans as a staging study for T-cell lymphomas: high rates of positivity do not result in frequent changes in stage. Blood. Nov 2006; 108:a2399.
Basch E, Goldfarb S. Electronic patient-reported outcomes (ePROs) for collecting sensitive information from patients. J Support Oncol. 2009.
Goldfarb S, Dickler M. Commentary on Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Breast Diseases: A Year Book Quarterly. Vol 20(3), October 2009 (in press).
Goldfarb S, Traina T, Dickler M. Bevacizumab in advanced breast cancer. Women’s Health. November 2009 (in press).
Ethan Basch, Xiaoyu Jia, Glenn Heller, Allison Barz, Laura Sit, Michael Fruscione, Mark Appawu, Alexia Iasonos, Thomas Atkinson, Shari Goldfarb, Ann Culkin, Mark G. Kris, and Deborah Schrag. Adverse Symptom Event Reporting by Patients versus Clinicians: Relationships with Clinical Outcomes. JNCI. 2009 (in press).